Christopher Marai
Stock Analyst at Nomura
(2.53)
# 2,083
Out of 4,818 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $7.34 | +12,979.02% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $46.20 | -28.57% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $3.56 | +2,428.09% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $242.16 | -69.44% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $3.51 | +355.84% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $118.17 | +231.73% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $1.50 | +2,166.67% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $59.44 | +286.94% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $13.01 | -7.76% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $9.61 | +97.81% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $1.44 | +2,886.11% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $7.34
Upside: +12,979.02%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $46.20
Upside: -28.57%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $3.56
Upside: +2,428.09%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $242.16
Upside: -69.44%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $3.51
Upside: +355.84%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $118.17
Upside: +231.73%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $1.50
Upside: +2,166.67%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $59.44
Upside: +286.94%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $13.01
Upside: -7.76%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $9.61
Upside: +97.81%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $1.44
Upside: +2,886.11%